Introduction to Oropharyngeal Cancer

What is/are Oropharyngeal Cancer?

Oropharyngeal Cancer - In addition to cervical cancer, anal, penile, and oropharyngeal cancers can be caused by the virus, which clearly affects men as well. ^[1] Methods Seventeen patients referred for curative radiotherapy for oropharyngeal cancer underwent standard CT-based dose planning and MR scans in the treatment position for planning (pMR), and at the 10th (MR10), 20th (MR20) and 30th (MR30) fraction (±2). ^[2] , for oropharyngeal cancer and leukemia), multivitamin use was not associated with the risk of cancer of the breast, prostate, or lung. ^[3] MATERIALS/METHODS Data were collected from oropharyngeal cancer patients that received RT with curative intent from 2015-2019. ^[4] A systematic literature review further confirmed that RPLN metastasis in oropharyngeal cancer is noted only in the presence of pN + disease at other neck levels, and isolated RPLN metastasis is extremely rare (1. ^[5] Background: To investigate the influence of sociodemographic factors and variables related to oral health services in oral and oropharyngeal cancer mortality in Brazil. ^[6] Most of the patients were of oropharyngeal cancers. ^[7] Results: 20 patients had oropharyngeal cancer. ^[8] OBJECTIVES This study compared oral cavity and oropharyngeal cancer incidence rates and trends among men in the active-duty military and the general population of the USA. ^[9] PURPOSE/OBJECTIVE(S) Automated tumor segmentation for oropharyngeal cancer (OPC) has the potential to improve treatment planning, response assessment, and clinical translation of imaging-based biomarkers. ^[10] The prognostic impact of human papillomavirus (HPV) in oropharyngeal cancer is generally acknowledged, and HPV‐status is assessed routinely in clinical practice. ^[11] In male musicians, there were statistically significant excesses in oropharyngeal cancer (4. ^[12] Introduction: India is a high-risk region for oropharyngeal cancer (OC) due to high prevalence of tobacco, betel nut, and alcohol and accounts for 30% of all new cases of oral cancer annually. ^[13] Oropharyngeal cancers were predominant in our cohort, while oral tongue is the most common anatomic site of H&N cancer in the US. ^[14] The base-case lifetime cost per patient for different stages of vulvar cancer/penile cancer/anal cancer/oral cancer/oropharyngeal cancer/laryngeal cancer falls within $17,120–$58,236. ^[15] 011) and oropharyngeal cancer (HR, 1. ^[16] Previous microbiome studies of oropharyngeal cancer have shown that there are differences in the oral microbiota between human papillomavirus (HPV)‐positive and HPV‐negative patients. ^[17] We decided to assess p16 expression status in patients with oropharyngeal cancer and retrospectively evaluate the outcomes of the treatment. ^[18] In this issue of Cancer, Ho et al recommend a convergence of human papillomavirus (HPV)-negative (HPV−) and HPV-positive (HPV+) oropharyngeal cancer (OPC) staging. ^[19] The purpose of the current study was to assess knowledge and attitudes about human papillomavirus (HPV) and HPV vaccination for oropharyngeal cancer (OPC) prevention in first-year through fourth-year dental students. ^[20] Although it was reported that DCLK1 is associated with poor prognosis in oropharyngeal cancers, very little is known about the molecular characterization of DCLK1 in HNSCC. ^[21] OBJECTIVES In this study, we aimed to analyze preoperative MRI images of oropharyngeal cancer patients who underwent surgical treatment, extracted radiomics features, and constructed a disease recurrence and death prediction model using radiomics features and machine-learning techniques. ^[22] Objective: To demonstrate the diagnostic ability of label-free, point-scanning, fiber-based Fluorescence Lifetime Imaging (FLIm) as a means of intraoperative guidance during oral and oropharyngeal cancer removal surgery. ^[23] Oral cavity and oropharyngeal cancers are leading pathologies, representing 3% of all new cancer cases in the United States. ^[24] We compared 1251 cases of oropharyngeal cancer treated from 2008 to 2017 before and after certification. ^[25] Background Positron-emission tomography (PET) is widely used to detect malignancies, but consensus on its prognostic value in oropharyngeal cancer has not been established. ^[26] A 67-year-old man underwent transoral endoscopy with a magnifying endoscope (EG-L600ZW7; FUJIFILM, Tokyo, Japan) and the video endoscopic system LASEREO (FUJIFILM) for surveillance after radiation therapy for oropharyngeal cancer. ^[27] Osteoradionecrosis (ORN) is a major side-effect of radiation therapy in oropharyngeal cancer (OPC) patients. ^[28] It is associated with different cancers, mainly cervical cancer, which remains the fourth most frequent cancer among women worldwide; it is also related to anogenital (anus, vulvar, vagina, and penis) and oropharyngeal cancers. ^[29] , Yokneam, Israel) in the treatment of oral and oropharyngeal cancers, specifically focusing on postoperative outcomes, pain, and quality of life (QoL). ^[30] Knowledge of HPV's role in oropharyngeal cancer was also low, at 30. ^[31] HPV infection can cause some types of cancer including female genital cancers (cervical cancer, vulvar) and male genital cancer as well as oropharyngeal cancers and genital warts. ^[32] Simple Summary This is a research article on oropharyngeal cancer (OPC). ^[33] OBJECTIVES Human papillomavirus infection (HPV) is the most common viral infection which is causes of cervical, penal, vulvar, anal and, oropharyngeal cancer. ^[34] PURPOSE/OBJECTIVE(S) To compare acute toxicity and quality of life (QOL) outcomes up to 3 months post chemoradiotherapy (CRT) versus CRT with nivolumab (iCRT) in locally advanced p16+ oropharyngeal cancer (OPC). ^[35] Although most infections resolve without clinical sequalae, persistent HPV infection can cause cervical, other anogenital, and oropharyngeal cancers and anogenital warts. ^[36] Simple Summary As the leading human papillomavirus (HPV)-related cancer, oropharyngeal cancer places a significant burden on patients, families, and health systems. ^[37] Women had a significant rise in oropharyngeal cancers (APC, 0. ^[38] Oropharyngeal cancer HPV genotyping was done using HPV genotypes 14 real-tm quant kit (SACACE, Italy). ^[39] The incidence of oropharyngeal cancer (OPC) is increasing remarkably among all head and neck cancers, mainly due to its association with the human papillomavirus (HPV). ^[40] Key Points Question What factors are associated with moderate to severe voice and speech symptoms among long-term survivors of oropharyngeal cancer (OPC)? Findings In this retrospective cohort study with cross-sectional survivorship survey administration, of 881 survivors of OPC who were included in analysis, 113 (12. ^[41] After the 2 years of follow-up, we aimed to evaluate at 5 years the impact of human papillomavirus (HPV) status, tobacco, and initial treatment approach on progression-free survival (PFS) and overall survival (OS) of patients with oropharyngeal cancer (OPC) in France. ^[42] The human papillomavirus (HPV) as a risk factor for oropharyngeal cancer was included in 94% of curricula and 87% also contained education about strategies to discuss prevention of HPV-related cancer. ^[43] Current results demonstrate that intrinsic fluorescence can provide useful contrast for intraoperative delineation of primary brain cancer at the resection margins and oral and oropharyngeal cancer. ^[44] BACKGROUND Oropharyngeal cancer (OPC) is an important cause of cancer-related mortality. ^[45] Timely diagnosis and treatment of oral and oropharyngeal cancers are central for the patient's survival. ^[46] Objective To access the prevalence and temporal trend of HPV infection in oropharyngeal cancer by analyzing the expression of the p16 protein. ^[47] PURPOSE This study investigated the prognostic potential of intra-treatment PET radiomics data in patients undergoing definitive (chemo)radiation therapy for oropharyngeal cancer (OPC) on a prospective clinical trial. ^[48] Oropharyngeal cancers related to the human papillomavirus are a growing segment of head and neck cancers throughout the world. ^[49] Head and neck cancers comprise a group of diseases with the most common being oral cavity and oropharyngeal cancers. ^[50]

transoral robotic surgery

Heterogeneity within studies examining transoral robotic surgery (TORS) for oropharyngeal cancer (OPC) has made it challenging to make clear conclusions on functional outcomes. ^[1] IMPLICATIONS FOR PRACTICE Transoral robotic surgery can provide a safe platform for de-escalation in carefully selected patients with early-stage human papillomavirus-related oropharyngeal cancer. ^[2] BACKGROUND We assessed long-term patient-reported dysphagia and xerostomia outcomes following definitive surgical management with transoral robotic surgery (TORS) in patients with oropharyngeal cancer (OPC) via a cross-sectional survey study. ^[3] Surgical treatment of human papillomavirus-mediated oropharyngeal cancer via transoral robotic surgery offers equivalent oncologic and functional outcomes relative to radiotherapy. ^[4] Besides Transoral Laser Microsurgery (TLM), a new robotic surgical technique namely Transoral Robotic Surgery (TORS) emerged for the first time as one of the two most prominent and widely used minimally invasive surgical approaches particularly for the treatment of oropharyngeal cancer, a sub-entity of head and neck cancers. ^[5] Purpose: Transoral robotic surgery (TORS) is most commonly undertaken as a minimally invasive approach for early staged oropharyngeal cancers (OPC), with good expectations for a functional recovery. ^[6] Patients with oropharyngeal cancer who undergo transoral robotic surgery (TORS) and have high‐risk features generally receive adjuvant chemoradiotherapy or trimodality therapy (TMT). ^[7] With increasing adoption of transoral robotic surgery (TORS) for oropharyngeal cancer (OPC), more patients may receive trimodality therapy. ^[8] BACKGROUND Transoral robotic surgery (TORS) has recently emerged as a surgical technique for oropharyngeal cancer. ^[9]

oral cavity cancer

The incidence of oropharyngeal cancers (OPC) and oral cavity cancers caused by HPV has increased in recent decades. ^[1] Six potential HPV surrogate biomarkers were analyzed using FFPE tissue samples from 153 HNSCC patients (n = 78 oropharyngeal cancer (OPSCC), n = 35 laryngeal cancer, n = 23 hypopharyngeal cancer, n = 17 oral cavity cancer): p16, CyclinD1, pRb, dual immunohistochemical staining of p16 and Ki67, HPV-DNA-PCR, and HPV-DNA-in situ hybridization (ISH). ^[2] Among men with penile cancer, four men were subsequently diagnosed with oral cavity cancer, one with oropharyngeal cancer and one with anal cancer. ^[3] Patients with oral cavity cancer (OCC) and oropharyngeal cancer (OPC) are often seen with locoregionally advanced disease requiring complex multimodality treatments. ^[4] HPV was prevalent in 50% of oropharyngeal cancers, 27% of laryngeal cancers, and 23% of oral cavity cancers. ^[5] OBJECTIVES The objectives of this study were to: I) discover novel human papillomaviruses (HPVs) using next generation sequencing (NGS) technology in oral rinse samples collected from oral cavity cancer (OCC) and oropharyngeal cancer (OPC) patients; II) determine the prevalence of novel HPVs in archived OCC and OPC tissue samples; and III) examine the frequency of novel oncogenic HPVs in cancer and non-cancer oral rinse samples using real-time PCR. ^[6] However, the role of HPV in oral cavity cancer may vary widely by subsite and may have increased over time, similar to trends observed for oropharyngeal cancer. ^[7]

human papillomavirus positive

Simple Summary Long-term survival in patients with oropharyngeal cancer is sparsely studied, but atypical recurrences in human papillomavirus-positive (HPV+) oropharyngeal cancer have been indicated. ^[1] Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk. ^[2] Purpose Studies on de-escalation in radiation therapy (RT) for human papillomavirus-positive (HPV(+)) oropharyngeal cancer (OPC) are currently ongoing. ^[3] Positron emission tomography-computed tomography (PET-CT)-guided surveillance with repeat imaging at 6 months for equivocal responders appears to be the most cost-effective approach for managing advanced, nodal human papillomavirus-positive oropharyngeal cancer following chemoradiation in Canada, according to a study published in Cancer. ^[4] 6062 Background: Human papillomavirus-positive oropharyngeal cancer (HPV OPC) portends a more favorable prognosis compared to HPV-negative cases. ^[5] In general, the staging changes for breast cancer and for human papillomavirus-positive oropharyngeal cancer were hailed as improvements, but the changes for testicular cancer were questioned as to their clinical relevance. ^[6]

human papillomavirus associated

The emergence of human papillomavirus-associated oropharyngeal cancer (HPVOPC) has resulted in an explosion of clinical research offering reduced toxicity and improved health-related quality of life (HRQL) through treatment de-escalation. ^[1] Human papillomavirus-associated oropharyngeal cancer (HPV-OPC) is a distinct clinical entity with a favorable prognosis compared with non-HPV-OPC. ^[2] BACKGROUND Favorable prognosis for Human papillomavirus-associated (HPV+) oropharyngeal cancer (OPC) led to investigation of response-adaptive de-escalation, yet long-term outcomes are unknown. ^[3] BACKGROUND This cross-sectional study examines patient-reported outcomes and functioning-based subgroups in human papillomavirus-associated oropharyngeal cancer survivors treated with chemoradiotherapy ≥12 months prior. ^[4] Favorable prognosis of human papillomavirus associated (HPV+) oropharyngeal cancer (OPC) has led to interest in treatment de-escalation. ^[5] A validated dysphagia symptom questionnaire and eating assessment tool was prospectively provided to patients presenting with untreated human papillomavirus-associated oropharyngeal cancer at the University of Maryland from July 2017 to December 2018. ^[6]

high risk human

High-risk human papillomavirus (HPV) is associated with the carcinogenesis of not only cervical cancer but anal, penile, vulvar, vaginal, and oropharyngeal cancers. ^[1] Numerous studies have shown that high-risk human polyomaviruses (HR-HPV) and Merkel cell polyomavirus (MCPyV) are two human tumor viruses associated with anogenetal and oropharyngeal cancers, and with Merkel cell carcinoma, respectively. ^[2] High-risk human papilloma virus (HR-HPV) is the etiological agent of cervical cancer and in some cases of head and neck cancer, specifically oropharyngeal cancer, but the role of HR-HPV in evoking neoplasia in BC is still unclear. ^[3] Persistent infection with high-risk human papillomaviruses (HPVs) is the major risk factor associated with development of anogenital and oropharyngeal cancers. ^[4] One change in the eighth edition, for example, is the introduction of a new staging system for high-risk human papillomavirus (HPV)-associated oropharyngeal cancers, recognizing the fact that these tumors have a biology and prognosis distinct from non-HPV associated cancers in the same anatomic location. ^[5]

intensity modulated proton

BACKGROUND AND PURPOSE To determine rates of xerostomia after intensity-modulated radiotherapy (IMRT) or intensity-modulated proton therapy (IMPT) for oropharyngeal cancer (OPC) and identify dosimetric factors associated with xerostomia risk. ^[1] The advanced form of PBT, intensity-modulated proton radiation therapy (IMPT), has been confirmed to reduce normal tissue complication probability (NTCP) as compared to conventional intensity-modulated photon-radiation therapy (IMRT) in patients with oropharyngeal cancer (OPC). ^[2] Purpose We compared work outcomes in patients with oropharyngeal cancer (OPC), randomized to intensity-modulated proton (IMPT) versus intensity-modulated photon therapy (IMRT) for chemoradiation therapy (CRT). ^[3] PURPOSE We report longitudinal patient-reported quality-of-life (QoL) outcomes related to xerostomia in patients with oropharyngeal cancer treated with intensity-modulated proton therapy (IMPT). ^[4]

vaginal vulvar penile

Human papillomavirus (HPV) is the leading cause of cervical cancer and has been implicated in several other cancer types including vaginal, vulvar, penile, and oropharyngeal cancers. ^[1] It is the only available vaccine that prevents cancer, including cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers. ^[2] 5% are attributable to HPV, including cervical, anal cancers, vaginal, vulvar, penile, and oropharyngeal cancers. ^[3] METHODS We adapted an existing mathematical model of HPV transmission and associated diseases to estimate the lifetime number of diagnosed cases of disease (genital warts; cervical intraepithelial neoplasia; and cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers) attributable to HPV infections that were acquired in 2018. ^[4]

neck squamous cell

Among head and neck squamous cell carcinomas (HNSCCs), oropharyngeal cancer (OPC) was historically thought to be a homogenous entity, mainly caused by excessive alcohol and tobacco consumption. ^[1] To evaluate the ability of post-chemo-radiotherapy (CRT) diffusion-weighted-MRI apparent diffusion coefficient (ADCmean) and 18F-FDG PET maximum standardized uptake value (SUVmax) to predict disease-free survival (DFS) in head and neck squamous cell carcinoma (HNSCC), and to determine whether this ability is influenced by human papillomavirus oropharyngeal cancer (HPV-OPC) status. ^[2] OBJECTIVE To determine the impact of Human Papilloma Virus (HPV) oropharyngeal cancer (OPC) status on the prediction of head and neck squamous cell cancer (HNSCC) chemoradiotherapy (CRT) outcomes with pre-treatment quantitative diffusion-weighted magnetic resonance imaging (DW-MRI). ^[3]

health related quality

BACKGROUND This exploratory, registry-based, cross-sectional study aimed to evaluate patients' health-related quality of life (HRQOL) in a subsite of oropharyngeal cancer: cancer of the base of the tongue (CBT). ^[1] OBJECTIVES To comprehensively explore the effect of several sociodemographic, patient and tumour related factors on the Health Related Quality of Life (HRQoL) of oral and oropharyngeal cancer patients. ^[2] To investigate the course of health-related quality of life (HRQOL) from diagnosis to 2 years follow-up among patients with oropharyngeal cancer (OPSCC), in relation to human papilloma virus (HPV) status. ^[3]

important public health

Background Oral and oropharyngeal cancers are considered an important public health problem around all world. ^[1] Background Oropharyngeal cancer is an important public health problem. ^[2] Background Oral and oropharyngeal cancers are considered important public health problems worldwide. ^[3]

human papillomavirus related

Moreover, efficacy outcomes are still not satisfactory with 5-year overall survival rates ranging between 40% and 50%, excluding the growing minority of human papillomavirus-related oropharyngeal cancer cases with a markedly better prognosis. ^[1] BACKGROUND Patients with human papillomavirus-related oropharyngeal cancers have excellent outcomes but experience clinically significant toxicities when treated with standard chemoradiotherapy (70 Gy). ^[2] Background: Studies on de-escalation in radiation therapy (RT) for human papillomavirus-related [HPV(+)] oropharyngeal cancer (OPC) are currently ongoing. ^[3]

treatment de escalation

The field has rapidly evolved with rising rates of HPV positive oropharyngeal cancers leading to treatment de-escalation studies that are currently ongoing. ^[1] Encouraging results from a number of studies investigating treatment de-escalation for HPV-associated oropharyngeal cancer support the notion that similar attempts may be feasible in HPV-associated anal cancer; however, the data to support this hypothesis are currently lacking. ^[2]

5 % 3

Oral cavity was the most common cancer site in our cohort (60%, 36 patients), followed by oropharyngeal cancer (15%, 9 patients), larynx (7%, 4 patients), hypopharynx (5%, 3 patients), parotid cancer (5%, 3 patients), unknown primary (5%, 3 patients) and nasal cavity/sinonasal cancer (3%, 2 patients). ^[1]

Associated Oropharyngeal Cancer

Smoking status at point of diagnosis is not used in defining risk groups for human papillomavirus (HPV)‐associated oropharyngeal cancer (OPC) despite its prognostic value in head and neck cancer. ^[1] Introduction: Inclusion of depth of invasion (DOI) and a separate classification for human papillomavirus (HPV)-associated Oropharyngeal Cancers (OPCs) are two of the many major changes in the 8th edition of the American Joint Committee on Cancer staging system. ^[2] Introduction Human papillomavirus (HPV)-associated oropharyngeal cancer rates are rising, particularly in males, although rates of other HPV-related cancers are decreasing. ^[3] CONCLUSIONS For patients with low risk HPV associated oropharyngeal cancer, radiotherapy and cetuximab had inferior failure-free survival without improvement in symptom burden or toxicity compared to radiotherapy and weekly cisplatin. ^[4] , this decline has been offset by a steady increase in human papillomavirus (HPV)-associated oropharyngeal cancers (OPC). ^[5] BACKGROUND The number of patients suffering from human papillomavirus (HPV)-associated oropharyngeal cancer has increased in recent decades. ^[6] The emergence of human papillomavirus-associated oropharyngeal cancer (HPVOPC) has resulted in an explosion of clinical research offering reduced toxicity and improved health-related quality of life (HRQL) through treatment de-escalation. ^[7] The best management of HPV-associated oropharyngeal cancer is under active investigation. ^[8] Human papillomavirus-associated oropharyngeal cancer (HPV-OPC) is a distinct clinical entity with a favorable prognosis compared with non-HPV-OPC. ^[9] Finally we discuss emerging evidence that locoregionally advanced HPV-associated oropharyngeal cancers that have high expression of CD103 positive CD8 T cells have an excellent prognosis and features that suggest increased probability of responding to anti-PD1/PD-L1, raising the possibility of incorporating these immune therapies as part of a de-escalation trial strategy. ^[10] BACKGROUND Early diagnosis of human papillomavirus (HPV) associated oropharyngeal cancer (OPC) is associated with improved survival. ^[11] Oral human papillomavirus (HPV) is associated with increasing rates of HPV‐associated oropharyngeal cancer (OPC) in men. ^[12] Encouraging results from a number of studies investigating treatment de-escalation for HPV-associated oropharyngeal cancer support the notion that similar attempts may be feasible in HPV-associated anal cancer; however, the data to support this hypothesis are currently lacking. ^[13] BACKGROUND This cross-sectional study examines patient-reported outcomes and functioning-based subgroups in human papillomavirus-associated oropharyngeal cancer survivors treated with chemoradiotherapy ≥12 months prior. ^[14] While there has been an overall decline of tobacco and alcohol-related head and neck cancer in recent decades, there has been an increased incidence of HPV-associated oropharyngeal cancer (OPC). ^[15] We aimed to identify a consensus of definition and management of close margins for human papilloma virus (HPV)‐associated oropharyngeal cancer without other risk factors. ^[16] PURPOSE/OBJECTIVE(S) Toxicity mitigation is a salient focus in the treatment of HPV-associated oropharyngeal cancer. ^[17] This retrospective single-centre study assessed patients with HPV-associated oropharyngeal cancer with distant metastasis treated in a tertiary referral center from 2005 to 2019. ^[18] On the other hand, the incidence of human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) is increasing. ^[19] We examined the impact of treatment modality on gastrostomy tube dependence and patient‐reported outcomes in human papillomavirus‐associated oropharyngeal cancer (HPV‐OPSCC). ^[20] One change in the eighth edition, for example, is the introduction of a new staging system for high-risk human papillomavirus (HPV)-associated oropharyngeal cancers, recognizing the fact that these tumors have a biology and prognosis distinct from non-HPV associated cancers in the same anatomic location. ^[21] INTRODUCTION HPV-associated oropharyngeal cancer (OPC) has one of the most rapidly rising incidences of any cancer in high-income countries. ^[22] BACKGROUND The incidence of human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) is increasing in high-income countries. ^[23] PURPOSE/OBJECTIVE(S) The percentage of tumor infiltrating lymphocytes (TILs) is indicative of immune response and prognostic in many malignancies, although TILs data within HPV associated oropharyngeal cancer are limited. ^[24] A validated dysphagia symptom questionnaire and eating assessment tool was prospectively provided to patients presenting with untreated human papillomavirus-associated oropharyngeal cancer at the University of Maryland from July 2017 to December 2018. ^[25] Introduction: In the last decade, the incidence of Human papilloma virus (HPV)-associated oropharyngeal cancer has increased and as high as 70% of all oropharyngeal cancers are caused by HPV. ^[26] The three most substantial 8th edition AJCC/UICC changes were the introduction of a novel staging for HPV‐associated oropharyngeal cancers, the addition of depth of invasion (DOI) to the oral cavity T category and the more universal introduction of extranodal extension (ENE) to N category for all nonvirally mediated head and neck cancers. ^[27] We searched MEDLINE, CINAHL, ScienceDirect, PsycINFO and JSTOR in August 2018 to identify studies of dental provider knowledge, perceived role and communication about HPV, HPV vaccination and HPV-associated oropharyngeal cancer (HPV-OPC). ^[28] Purpose Human papillomavirus (HPV)–associated oropharyngeal cancer (OPC) commonly affects people of working age, yet there is limited data regarding the return-to-work experience in this cohort. ^[29]

Related Oropharyngeal Cancer

IMPLICATIONS FOR PRACTICE Transoral robotic surgery can provide a safe platform for de-escalation in carefully selected patients with early-stage human papillomavirus-related oropharyngeal cancer. ^[1] A biomarker that is useful for the detection of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) and cancer of unknown primary (CUP) is indispensable. ^[2] Purpose The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. ^[3] p16 immunostaining is used to diagnose HPV-related oropharyngeal cancer. ^[4] Human papillomavirus (HPV) infections are commonly recognized in the United States with associations to cancers of the vulva, vagina, penis, anus, and oropharynx; the incidence of HPV-related oropharyngeal cancer (OPC) in the United States is on the rise. ^[5] In the management of HPV-related oropharyngeal cancer, de-intensification of treatment has been attempted; however, no such attempt is performed in the management of cervical cancer. ^[6] Though this intervention is welcomed by the dental fraternity it is not without its challenges especially in human papilloma virus (HPV) related oropharyngeal cancer (OPC) which has seen a phenomenal rise over the past decade. ^[7] In contrast to tobacco-related mucosal cancer, human papilloma virus (HPV)-related oropharyngeal cancers are common in younger males (3). ^[8] OBJECTIVES To determine whether up-front trans-oral robotic surgery (TORS) for clinically-staged locally-advanced human papillomavirus (HPV)-related oropharyngeal cancer is associated with oncologic and survival outcomes comparable to early-stage (cT1/T2) tumors. ^[9] PURPOSE/OBJECTIVE(S) Patients with HPV-related oropharyngeal cancers (HPV+OPC) are known to have a superior locoregional control when compared to HPV-unrelated oropharyngeal cancers (HPV-OPC). ^[10] The sample size of 99 patients may be far less a number to help arrive at a conclusion especially when rate of HPV-related oropharyngeal cancers is increasing at 5% per year. ^[11] To assess whether this differs in human papillomavirus–related oropharyngeal cancer (HPV-OPC) and whether the MRI timing impacts on the ability to predict treatment success. ^[12] OBJECTIVES Analyze how otolaryngologists approach HPV-related oropharyngeal cancer in terms of patient selection for transoral surgery, perceptions of treatment related risks and benefits, and adjuvant treatment decisions. ^[13] Most relevant diagnostic and therapeutic changes from the last guideline have been updated: introduction of sentinel node biopsy in early oral/oropharyngeal cancer treated with surgery, concomitant radiotherapy with weekly cisplatin 40 mg/m2 in the adjuvant setting, new approaches for HPV-related oropharyngeal cancer and new treatments with immune-checkpoint inhibitors in recurrent/metastatic disease. ^[14] Our understanding of human papillomavirus (HPV)‐related oropharyngeal cancer (OPC) and its molecular basis continues to evolve and produce important insights into customized therapeutic strategies. ^[15] Case‐control studies from the early 2000s demonstrated that human papillomavirus–related oropharyngeal cancer (HPV‐OPC) is a distinct entity associated with number of oral sex partners. ^[16] OBJECTIVES/HYPOTHESIS We aim to 1) evaluate trends in adjuvant treatment of human papilloma virus (HPV)-related oropharyngeal cancer; 2) assess change in complications and functional outcomes over time; and 3) assess change in overall and disease-free survival (DFS) over time. ^[17] This review explores how human papillomavirus‐related oropharyngeal cancer affects health‐related quality of life (HR‐QoL) and the role patient‐reported outcomes (PROs) can play in optimizing treatment. ^[18] INTRODUCTION Optimal surveillance paradigms for survivors of early stage human papillomavirus (HPV)-related oropharyngeal cancer are not well defined. ^[19] Moreover, efficacy outcomes are still not satisfactory with 5-year overall survival rates ranging between 40% and 50%, excluding the growing minority of human papillomavirus-related oropharyngeal cancer cases with a markedly better prognosis. ^[20] BACKGROUND Patients with human papillomavirus-related oropharyngeal cancers have excellent outcomes but experience clinically significant toxicities when treated with standard chemoradiotherapy (70 Gy). ^[21] Although the incidence of HPV-related oropharyngeal cancers among males is increasing, few studies have been published on HPV knowledge and vaccine acceptability among males. ^[22] To determine the opinions of parents of children age 9 to 18 on HPV-related oropharyngeal cancers (OPC); the associations with education level, socioeconomic status, and having a family member/friend with OPC; and the main concerns against having a vaccination. ^[23] Previous guideline for the treatment of head and neck cancer has been updated to incorporate new evidence, which includes Equivalence to standard treatments of sentinel node biopsy in early oral/oropharyngeal cancer treated with surgery, concomitant radiotherapy with weekly cisplatin 40 mg/ m2 in the adjuvant setting, new therapeutic approaches for HPV-related oropharyngeal cancer patients and the new standard treatment with immune-checkpoint inhibitors in recurrent/metastatic disease [1]. ^[24] Rates of human papillomavirus (HPV)–related oropharyngeal cancer have been rising among U. ^[25]

Positive Oropharyngeal Cancer

The field has rapidly evolved with rising rates of HPV positive oropharyngeal cancers leading to treatment de-escalation studies that are currently ongoing. ^[1] Patients with HPV-positive oropharyngeal cancer may benefit the most from additive double checkpoint inhibition, which is presumably due to the higher amount of infiltrating immune cells. ^[2] MATERIALS/METHODS 184 and 177 prospectively enrolled patients for de-escalated CRT for HPV-positive oropharyngeal cancer submitted PROs at 6 and 12 months, respectively using PRO-CTCAE questionnaire. ^[3] Human papillomavirus (HPV)-positive oropharyngeal cancers (OPC) are increasing due to infection with the virus. ^[4] Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk. ^[5] 6037 Background: Among HPV-positive Oropharyngeal Cancer (OPC) patients (pts), some has a less favorable prognosis (T4, N2/N3, smokers >10 pack-year [p/y]). ^[6] Purpose The study aimed to analyse radiological differences in computed tomography (CT) findings and texture analysis between cystic lymph node metastases (CNM) in human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) and second branchial cleft cysts (2nd BC). ^[7] The cost utility of image‐guided surveillance using computed tomography (CT) and positron emission tomography (PET)‐CT to planned postradiation neck dissection (PRND) was compared for the management of advanced nodal human papillomavirus‐positive oropharyngeal cancer following chemoradiation. ^[8] The American Joint Committee on Cancer (AJCC) released a new staging system for human papilloma virus (HPV) positive oropharyngeal cancer (OPC) in their eighth edition. ^[9] Analysis of 105 HPV-positive oropharyngeal cancers by whole genome sequencing detects viral integration in 77%, revealing five statistically significant integration hotspots near genes that regulate epithelial stem cell maintenance (i. ^[10] Positron emission tomography-computed tomography (PET-CT)-guided surveillance with repeat imaging at 6 months for equivocal responders appears to be the most cost-effective approach for managing advanced, nodal human papillomavirus-positive oropharyngeal cancer following chemoradiation in Canada, according to a study published in Cancer. ^[11] Diagnostic workup confirmed the diagnosis of locally-advanced p16-positive oropharyngeal cancer (OPC) with a surprising histology of small cell cancer, suggesting a human papilloma virus (HPV)-related oropharyngeal cancer with small cell differentiation. ^[12] HPV-positive oropharyngeal cancer can develop without exposure to established risk factors such as tobacco use or excessive alcohol consumption. ^[13] 6062 Background: Human papillomavirus-positive oropharyngeal cancer (HPV OPC) portends a more favorable prognosis compared to HPV-negative cases. ^[14] BACKGROUND The incidence of HPV positive oropharyngeal cancer is increasing in Taiwan. ^[15] In general, the staging changes for breast cancer and for human papillomavirus-positive oropharyngeal cancer were hailed as improvements, but the changes for testicular cancer were questioned as to their clinical relevance. ^[16] [5] recently reported the results of a randomized noninferiority trial comparing radiotherapy plus cetuximab to radiotherapy plus cisplatin in patients with papillomavirus-positive oropharyngeal cancer. ^[17] [1] on a relevant issue of therapy de-intensification in p16/human papilloma virus (HPV)-positive oropharyngeal cancers. ^[18]

Advanced Oropharyngeal Cancer

High‐dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). ^[1] Background: Concurrent chemoradiation had been the standard of care for locally advanced oropharyngeal cancers. ^[2] Objectives: The aim of this study is to assess dysphagia severity after treatment in advanced oropharyngeal cancer patients treated with concurrent chemo-radiation. ^[3]

Driven Oropharyngeal Cancer

However, the molecular cargo of salivary exosomes derived from HPV-driven oropharyngeal cancer (HPV-driven OPC) remains unelucidated. ^[1] Simple Summary Serum antibodies against human papillomavirus 16 (HPV16) proteins are associated with HPV-driven oropharyngeal cancer (HPV-OPC). ^[2] Patients with human papillomavirus (HPV)‐driven oropharyngeal cancer (OPC) experience better survival than those with HPV‐negative OPC. ^[3]

Negative Oropharyngeal Cancer

The present study aimed to evaluate the prognostic factors in human papillomavirus (HPV)‐positive and HPV‐negative oropharyngeal cancer (OPC) treated with definitive radiotherapy. ^[1] BACKGROUND/OBJECTIVES We evaluate the performance between the TNM-8 versus TNM-7 cN-classification and explore the relative prognostic contribution of radiologic extranodal extension (rENE) for HPV-negative oropharyngeal cancer (HPV-OPC). ^[2]